公开(公告)号：US11384073B2

公开(公告)日：2022-07-12

申请号：US17127350

申请日：2020-12-18

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Jingshan Shen ,  Yang He ,  Zhen Wang ,  Jianfeng Li ,  Yongjian Liu ,  Jin Suo ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Yu Wang ,  Xiangrui Jiang ,  Rongxia Zhang ,  Hualiang Jiang

IPC分类号： C07D409/12

摘要： The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.

公开(公告)号：US20210309648A1

公开(公告)日：2021-10-07

申请号：US17127350

申请日：2020-12-18

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Jingshan Shen ,  Yang He ,  Zhen Wang ,  Jianfeng Li ,  Yongjian Liu ,  Jin Suo ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Yu Wang ,  Xiangrui Jiang ,  Rongxia Zhang ,  Hualiang Jiang

IPC分类号： C07D409/12

摘要： The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.

公开(公告)号：US10093679B2

公开(公告)日：2018-10-09

申请号：US15509796

申请日：2015-09-11

申请人： SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Jingshan Shen ,  Zheng Liu ,  Zhen Wang ,  Guanghui Tian ,  Jianfeng Li ,  Xiaojun Yang

IPC分类号： C07D261/20 ,  C07D495/04 ,  A61K31/33 ,  A61K31/381 ,  C07D209/14 ,  C07D307/77 ,  C07D231/56 ,  C07D275/04 ,  C07D333/20 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425 ,  C07D333/46

摘要： Disclosed are aminosulfonyl-based compounds represented by the general formula I or tautomers, enantiomers, racemates or pharmaceutically acceptable salts thereof, a method for preparing the same, pharmaceutical compositions and uses thereof. The compounds can be used to treat epilepsy, convulsions, obesity and the like.

公开(公告)号：US10100044B2

公开(公告)日：2018-10-16

申请号：US15030331

申请日：2014-10-20

申请人： SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Zheng Liu ,  Chunhui Wu ,  Yongjian Liu ,  Rongxia Zhang ,  Yang He ,  Guanghui Tian ,  Jingshan Shen

IPC分类号： C07D333/70 ,  C07D409/12 ,  C07D333/54

摘要： The present invention relates to the methods for preparing brexpiprazole, the analogs, key intermediates, and salts thereof, specifically, the present invention relates to a new method for preparing brexpiprazole, the analogs, key intermediates, and salts thereof, and the key intermediates, and salts thereof provided during the preparation. The preparation method has a mild reaction condition, stable intermediate, easy operation, and uses cheap and easy-to-get reagents, thus it saves the synthesis cost, shortens the production cycle, improves the yield and product quality, and is suitable for mass production.

公开(公告)号：US11434226B2

公开(公告)日：2022-09-06

申请号：US16736300

申请日：2020-01-07

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Jingshan Shen ,  Yang He ,  Weiming Chen ,  Jianfeng Li ,  Guanghui Tian ,  Xudong Gong ,  Zhen Wang ,  Rongxia Zhang ,  Yongjian Liu ,  Hualiang Jiang

IPC分类号： C07D403/12 ,  A61K45/06

摘要： The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof.

公开(公告)号：US10174011B2

公开(公告)日：2019-01-08

申请号：US15124264

申请日：2015-03-09

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANDONG CO., LTD.

发明人： Hualiang Jiang ,  Zhen Wang ,  Jianfeng Li ,  Rongxia Zhang ,  Yang He ,  Yongjian Liu ,  Minghao Bi ,  Zheng Liu ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Chunhui Wu ,  Yu Wang ,  Xiangrui Jiang ,  Jingjing Yin ,  Guan Wang ,  Jingshan Shen

IPC分类号： C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00 ,  A61K31/496 ,  A61K31/519 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/55

摘要： The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

公开(公告)号：US20140046074A1

公开(公告)日：2014-02-13

申请号：US13982733

申请日：2012-01-31

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Qiang Zhang ,  Rongxia Zhang ,  Guanghui Tian ,  Jianfeng Li ,  Fuqiang Zhu ,  Xiangrui Jiang ,  Jingshan Shen

IPC分类号： C07C213/02 ,  C07C59/64 ,  C07C235/34 ,  C07C309/75 ,  C07C309/66 ,  C07C43/225 ,  C07C215/54 ,  C07D263/26 ,  C07C43/23

CPC分类号： C07C235/34 ,  C07C17/16 ,  C07C41/26 ,  C07C43/225 ,  C07C43/23 ,  C07C59/64 ,  C07C59/68 ,  C07C213/02 ,  C07C215/54 ,  C07C217/62 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07D263/26 ,  C07D263/52 ,  Y02P20/582 ,  C07C22/04

摘要： The present invention relates to a (2R, 3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process.

摘要翻译： 本发明涉及式I所示的（2R，3R）-3-（3-取代苯基）-2-甲基正戊酰胺化合物及其制备方法，其中取代基如本说明书中所定义 ，本发明还涉及上述化合物在制备他喷他多II或其药学上可接受的盐中的用途，以及参与制备方法的中间体。

公开(公告)号：US11731965B2

公开(公告)日：2023-08-22

申请号：US16639394

申请日：2018-08-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Yang He ,  Xiangrui Jiang ,  Jianfeng Li ,  Yu Wang ,  Zhen Wang ,  Weiming Chen ,  Fuqiang Zhu ,  Chunhui Wu ,  Rongxia Zhang ,  Jingshan Shen ,  Hualiang Jiang

IPC分类号： C07D455/03 ,  C07D498/14 ,  A61P25/20

CPC分类号： C07D455/03 ,  A61P25/20 ,  C07D498/14

摘要： The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.

公开(公告)号：US20240166680A1

公开(公告)日：2024-05-23

申请号：US18286416

申请日：2022-04-12

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Jingshan Shen ,  Yuanchao Xie ,  Tianwen Hu

IPC分类号： C07H19/23 ,  A61P31/14 ,  A61P31/16 ,  C07H19/067 ,  C07H19/10

CPC分类号： C07H19/23 ,  A61P31/14 ,  A61P31/16 ,  C07H19/067 ,  C07H19/10

摘要： The present invention relates to a nucleoside analog represented by the following formula and a use thereof. Specifically, the present invention relates to a nucleoside analog represented by the following formula or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and a use thereof in preparation of (a) an inhibitor for inhibiting replication of coronaviruses, paramyxoviruses, influenza viruses, flaviviruses, filoviruses, bunya viruses and/or arenaviruses, and/or (b) a medicine for treating and/or preventing or alleviating a disease caused by infection of coronaviruses, paramyxoviruses, influenza viruses, flaviviruses, filoviruses, bunya viruses and/or arenaviruses.

公开(公告)号：US11919923B2

公开(公告)日：2024-03-05

申请号：US17996430

申请日：2021-04-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yuanchao Xie ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.